Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Guangzhou Baiyunshan Pharmaceutical Holdings Co EV-to-EBITDA?
Guangzhou Baiyunshan Pharmaceutical Holdings CoFRA:GU5 70 EV-to-EBITDA is 10.45 as of Aug. 19, 2026, which is 1% below its 10-year median of 10.54. GuruFocus rates FRA:GU5 with a GF Score™ of 70/100 and a GF Value™ of €2.43 (Significantly Undervalued). The stock has 6 warning signs investors should review. Among 98 Medical Distribution companies, Guangzhou Baiyunshan Pharmaceutical Holdings Co ranks worse than 63.27% on this metric.
FRA:GU5's EV-to-EBITDA is ranked worse than 63.27% of 98
companies
in the Medical Distribution industry
Industry Median: 8.565
vs FRA:GU5: 10.00
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Guangzhou Baiyunshan Pharmaceutical Holdings Co's PE Ratio (TTM) for today is calculated as:
Guangzhou Baiyunshan Pharmaceutical Holdings Co's share price for today is €1.63.
Guangzhou Baiyunshan Pharmaceutical Holdings Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.224.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guangzhou Baiyunshan Pharmaceutical Holdings Co EV-to-EBITDA Chart
Guangzhou Baiyunshan Pharmaceutical Holdings Co Annual Data
For the Medical Distribution subindustry, Guangzhou Baiyunshan Pharmaceutical Holdings Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guangzhou Baiyunshan Pharmaceutical Holdings Co EV-to-EBITDA vs Medical Distribution Industry
Guangzhou Baiyunshan Pharmaceutical Holdings Co's current Enterprise Value is €5,234 Mil.
Guangzhou Baiyunshan Pharmaceutical Holdings Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €501 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5) has a EV-to-EBITDA of 10.45 as of Aug. 19, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Guangzhou Baiyunshan Pharmaceutical Holdings Co. This is near median its historical median of 10.54. Over the past decade, Guangzhou Baiyunshan Pharmaceutical Holdings Co's EV-to-EBITDA has ranged from 6.23 to 18.03. According to the industry distribution chart, Guangzhou Baiyunshan Pharmaceutical Holdings Co ranks #62 out of 98 companies in the Medical Distribution industry, placing it in the top 63.3%.
Is Guangzhou Baiyunshan Pharmaceutical Holdings Co's EV-to-EBITDA too high?
Guangzhou Baiyunshan Pharmaceutical Holdings Co's current EV-to-EBITDA of 10.45 is near median its 10-year median of 10.54. Over the past 10 years, this metric has ranged from a low of 6.23 to a high of 18.03. The Medical Distribution industry median EV-to-EBITDA is 8.57. Guangzhou Baiyunshan Pharmaceutical Holdings Co's value of 10.45 is 22% above this industry median. Based on the distribution chart, Guangzhou Baiyunshan Pharmaceutical Holdings Co ranks #62 out of 98 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Guangzhou Baiyunshan Pharmaceutical Holdings Co has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Guangzhou Baiyunshan Pharmaceutical Holdings Co's EV-to-EBITDA compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Guangzhou Baiyunshan Pharmaceutical Holdings Co ranks #62 out of 98 companies for EV-to-EBITDA. This places Guangzhou Baiyunshan Pharmaceutical Holdings Co in the lower half of its industry. The industry median EV-to-EBITDA is 8.57. Guangzhou Baiyunshan Pharmaceutical Holdings Co's value of 10.45 is 22% above this benchmark. Historically, Guangzhou Baiyunshan Pharmaceutical Holdings Co's own EV-to-EBITDA has ranged from 6.23 to 18.03 over the past decade. While the company's 10-year median is 10.54 vs. the industry median of 8.57, Guangzhou Baiyunshan Pharmaceutical Holdings Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Distribution company?
The median EV-to-EBITDA among Medical Distribution companies is 8.57, based on 98 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Guangzhou Baiyunshan Pharmaceutical Holdings Co's current EV-to-EBITDA of 10.45 is 22% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Guangzhou Baiyunshan Pharmaceutical Holdings Co. For the Medical Distribution industry, the median EV-to-EBITDA is 8.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Guangzhou Baiyunshan Pharmaceutical Holdings Co's current EV-to-EBITDA is 10.45, which is near median its own 10-year median of 10.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guangzhou Baiyunshan Pharmaceutical Holdings Co stock overvalued right now?
Based on GuruFocus' analysis, Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5) is currently considered Significantly Undervalued. The stock's GF Value™ is €2.43, compared to a current price of €1.63 — trading 32.9% below its estimated fair value. The current EV-to-EBITDA is 10.45, which is near median its 10-year median of 10.54 and 22% above the Medical Distribution industry median of 8.57. Guangzhou Baiyunshan Pharmaceutical Holdings Co's overall GF Score™ is 70/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5), the current EV-to-EBITDA is 10.45 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5) Overvalued in 2026?
Based on GuruFocus' analysis, Guangzhou Baiyunshan Pharmaceutical Holdings Co stock appears to be undervalued.
The current stock price of €1.63 is trading 32.9% below its estimated GF Value™ of €2.43.
GuruFocus considers Guangzhou Baiyunshan Pharmaceutical Holdings Co to be Significantly Undervalued.
Key valuation signals for FRA:GU5:
EV-to-EBITDA: 10.45 (near median its 10-year median of 10.54)
GF Value™: €2.43 vs. price of €1.63 (32.9% below fair value)
Industry Position: 22% above the Medical Distribution median (#62 of 98)
No single metric tells the full story. See the FRA:GU5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd is engaged in the pharmaceutical and healthcare industry, focusing on the development of a full industrial chain covering research, manufacturing, and distribution. The group operates through five reportable segments. The Modern Chinese Medicine segment involves the R&D, manufacturing, and sale of proprietary Chinese and natural medicines. The Chemical Pharmaceutical Technology segment focuses on chemical drugs, APIs, and intermediates. The Natural Beverages segment produces and sells health-oriented beverage products. The Pharmaceutical Commerce segment is engaged in the wholesale, retail, and import/export of medicines and medical devices. The Other Segments include biotechnology innovation, consumer health, and medical services.
70GF Score
Get the complete analysis for FRA:GU5
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:GU5 has been successfully added to your 
